Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

While Bristol-Myers Squibb’s recent quarterly performance showed encouraging progress in top-line growth and cost management, its true transformation will stem from its pipeline, the BMO analyst ...

Around the same time, the prototype of the Squibb logo was designed. The logo represented product uniformity, purity, efficacy and reliability based on research. By 1924, Bristol-Myers' gross ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings of $1.80 ...

PRINCETON, N.J., November 05, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024.

AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...

Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us. To my immediate right is Samit Hirawat. He is the Chief Medical Officer and Head of ...